A Phase 3 trial of eloralintide in adults with obesity and type 2 diabetes begins in the registry
Phase IIIP1Primary public evidenceTrial registry record
NCT07282600 lists a start date of 15 December 2025 for a Phase 3 placebo-controlled trial of once-weekly eloralintide in adults with obesity or overweight and type 2 diabetes. It lists 1,035 planned participants, 148 locations and a primary completion date of January 2028.
1,035
Planned participants, as recorded in the registry
January 2028
Primary completion date listed in the registry
Background and context
What the record describes
ENLIGHTEN-2 compares once-weekly eloralintide with placebo, double-blind, in adults with obesity or overweight who also have type 2 diabetes. The primary endpoint is percent change in body weight from baseline to week 64.
Who can take part
Adults need type 2 diabetes on stable treatment for at least 90 days, and a BMI of at least 27. The record excludes recent use of amylin analogs, GLP-1 receptor agonists, GIP/GLP-1 receptor agonists or insulin in the 90 days before screening. Participation lasts about 75 weeks.
Glucose is a secondary measure
No results are posted. HbA1c is listed as a secondary measure only, and the record names no separate primary glucose endpoint.
Trial record: ClinicalTrials.gov NCT07282600, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
